Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Monday. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 117.39% from the company’s current price.

The analysts wrote, “Celldex Receives a Buy from Cantor Fitzgerald | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=ae16fd92b5&wpp_id=456014’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Celldex Receives a Buy from Cantor Fitzgerald”

Several other equities research analysts have also weighed in on CLDX. Wedbush reissued a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Jefferies Group restated a “hold” rating and set a $5.00 price target (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Finally, Brean Capital initiated coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $16.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Celldex Therapeutics has an average rating of “Hold” and an average price target of $7.75.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 0.72% on Monday, hitting $4.17. The stock had a trading volume of 949,691 shares. The firm’s 50-day moving average is $3.75 and its 200-day moving average is $4.17. The company’s market cap is $419.27 million. Celldex Therapeutics has a one year low of $2.96 and a one year high of $18.62.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The business had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million. During the same quarter last year, the company earned ($0.33) EPS. The business’s quarterly revenue was down 36.4% on a year-over-year basis. On average, analysts expect that Celldex Therapeutics will post ($1.34) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. State Street Corp increased its position in shares of Celldex Therapeutics by 158.9% in the first quarter. State Street Corp now owns 8,561,225 shares of the biopharmaceutical company’s stock valued at $32,362,000 after buying an additional 5,254,100 shares during the period. Vanguard Group Inc. increased its position in shares of Celldex Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 7,263,339 shares of the biopharmaceutical company’s stock valued at $31,886,000 after buying an additional 492,102 shares during the period. Columbia Wanger Asset Management LLC increased its position in shares of Celldex Therapeutics by 76.8% in the second quarter. Columbia Wanger Asset Management LLC now owns 5,261,934 shares of the biopharmaceutical company’s stock valued at $23,100,000 after buying an additional 2,285,534 shares during the period. BlackRock Fund Advisors increased its position in shares of Celldex Therapeutics by 4.6% in the second quarter. BlackRock Fund Advisors now owns 3,767,356 shares of the biopharmaceutical company’s stock valued at $16,539,000 after buying an additional 167,033 shares during the period. Finally, RTW Investments LLC increased its position in shares of Celldex Therapeutics by 27.8% in the second quarter. RTW Investments LLC now owns 1,264,227 shares of the biopharmaceutical company’s stock valued at $5,550,000 after buying an additional 274,851 shares during the period. Institutional investors own 78.41% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.